CIOReview | | 19 NOVEMBER 2022Chris Braithwaite is SVP and Global Head of Drug Development Technology at Novartis. Prior to working at Novartis, he also worked as the VP of Global Commercial IT at AstraZeneca, based in the United States. He is a dynamic senior technology executive with 20+ years of pharmaceutical experience in strategy delivery, digital transformation, and talent building. His proven track record of success in building scaled, high-performing teams and managing rapid change has brought solid business results through innovative investments in data and technology.In an interview with Pharma Tech Outlook Magazine, Chris Braithwaite discusses the future of cloud disrupting development technology in the pharmaceutical industry.As a dynamic senior technology executive with 20+ years of pharmaceutical experience in strategy delivery, digital transformation, and talent building, how do you see the pharmaceutical industry evolving?The major transition that is currently taking place in the industry is the use of vast amounts of data to drive decision-making regarding the efficacy and safety of products for clinical trials and regulatory submissions. While there have been data-driven initiatives in the past, they usually revolved around fairly discrete data sets. Now, we are seeing much larger data sets being integrated into the decision-making process in order to, not only satisfy regulators, but also make critical business decisions about the portfolio we manage.The other aspect is the ability to generate data. This will aid in comprehending how drugs perform in clinical and commercial settings, while also in recognizing the therapeutic benefits allowing for more informed decision-making. Some companies in the sector are leading the way and have made critical portfolio decisions, starting to decrease the time to reach medicine to patients. This break through involves driving clinical development life-cycle in a very data-driven manner. What are some of the challenges existing in the pharma-tech space today? How is the cloud driving change for pharma?Traditionally, we've had to think of our organization as discreet components because discovering, developing, manufacturing, and commercialization of medicines has been a fairly sequential processes with discrete interfaces. It is extremely tough to get those things to work effectively together and get a clearer view of what's going on across those separate business operations as they're so vast and scaled. The cloud enables us to expand and assists with managing the data that drives organizational success. CLOUD COMPUTING DRIVING CHANGE IN PHARMA INDUSTRYBy Chris Braithwaite, SVP and Global Head of Drug Development Technology, NovartisChris BraithwaiteCXO INSIGHTS
< Page 9 | Page 11 >